These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 11240421)

  • 21. "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.
    Moser HW; Moser AB; Hollandsworth K; Brereton NH; Raymond GV
    J Mol Neurosci; 2007 Sep; 33(1):105-13. PubMed ID: 17901554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adrenoleukodystrophy in Israel: a genetic, clinical and biochemical study.
    Chemke J; Lieberman E; Carmi R; Abarbanel Y; Costeff H; Goldhammer Y; Moser HW
    Isr J Med Sci; 1984 Dec; 20(12):1123-32. PubMed ID: 6097565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diet therapy in the treatment of neuropediatric disorders].
    Chaves-Carballo E
    Rev Neurol; 2003 Aug 1-15; 37(3):267-74. PubMed ID: 12938059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
    Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
    Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy of X-linked adrenoleukodystrophy.
    Moser HW
    NeuroRx; 2006 Apr; 3(2):246-53. PubMed ID: 16554262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adrenoleukodystrophy: a link between adrenal insufficiency and school performance.
    Bakos JT; Goen P; Ogden A; Brown FR; Karaviti LP
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2869-72. PubMed ID: 7559867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [X-linked adrenoleukodystrophy].
    Aubourg P
    Ann Endocrinol (Paris); 2007 Dec; 68(6):403-11. PubMed ID: 17532287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Adrenoleukomyeloneuropathy. A familial case].
    Gastaut JL; Pellissier JF; Pfister B; Figarella-Branger D; Michel B
    Rev Neurol (Paris); 1988; 144(5):338-46. PubMed ID: 3420352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lorenzo's oil: a reassessment.
    Poulos A; Robertson EF
    Med J Aust; 1994 Mar; 160(6):315-7. PubMed ID: 8133809
    [No Abstract]   [Full Text] [Related]  

  • 30. [Symptomatic heterozygotic adrenoleukodystrophy in adults. 10 cases].
    Ménage P; Carreau V; Tourbah A; Fontaine B; Paturneau-Jouas M; Gout O; Lubetzki C; Baumann N; Lyon-Caen O
    Rev Neurol (Paris); 1993; 149(8-9):445-54. PubMed ID: 8009141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adrenomyeloneuropathy. Endocrine, clinical and biological study of 4 cases].
    Kuhn JM; Emy P; Scherrer H; Simon D; Detilleux M; Bricaire H; Luton JP
    Ann Med Interne (Paris); 1984; 135(7):537-41. PubMed ID: 6517426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the preventive effect of glyceryl trioleate-trierucate ("Lorenzo's oil") therapy in X-linked adrenoleukodystrophy: results of two concurrent trials.
    Moser HW; Raymond GV; Koehler W; Sokolowski P; Hanefeld F; Korenke GC; Green A; Loes DJ; Hunneman DH; Jones RO; Lu SE; Uziel G; Giros ML; Roels F
    Adv Exp Med Biol; 2003; 544():369-87. PubMed ID: 14713253
    [No Abstract]   [Full Text] [Related]  

  • 33. Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.
    Deon M; Garcia MP; Sitta A; Barschak AG; Coelho DM; Schimit GO; Pigatto M; Jardim LB; Wajner M; Giugliani R; Vargas CR
    Metab Brain Dis; 2008 Mar; 23(1):43-9. PubMed ID: 18026827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and genetic aspects of X-linked adrenoleukodystrophy.
    Gärtner J; Braun A; Holzinger A; Roerig P; Lenard HG; Roscher AA
    Neuropediatrics; 1998 Feb; 29(1):3-13. PubMed ID: 9553942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adrenoleukodystrophy: magnetic resonance follow-up after Lorenzo's oil therapy.
    Duchesne N; Dufour M; Bouchard G; Grondin P; Lemieux B
    Can Assoc Radiol J; 1995 Oct; 46(5):386-91. PubMed ID: 7552831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normal natural killer cell activity in a patient with adrenoleukodystrophy treated with Lorenzo's oil.
    Tanaka M; Koike R; Kuwabara T
    Neurodegeneration; 1996 Jun; 5(2):192-4. PubMed ID: 8819141
    [No Abstract]   [Full Text] [Related]  

  • 37. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy.
    Fourcade S; López-Erauskin J; Galino J; Duval C; Naudi A; Jove M; Kemp S; Villarroya F; Ferrer I; Pamplona R; Portero-Otin M; Pujol A
    Hum Mol Genet; 2008 Jun; 17(12):1762-73. PubMed ID: 18344354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lorenzo's oil. A realistic presentation of two parents' fight against adrenoleukodystrophy].
    Söderfeldt B
    Lakartidningen; 1993 May; 90(20):1969-72. PubMed ID: 8502039
    [No Abstract]   [Full Text] [Related]  

  • 39. Monitoring of very long-chain fatty acids levels in X-linked adrenoleukodystrophy, treated with haematopoietic stem cell transplantation and Lorenzo's Oil.
    Stradomska TJ; Drabko K; Moszczyńska E; Tylki-Szymańska A
    Folia Neuropathol; 2014; 52(2):159-63. PubMed ID: 25118901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.
    Moser HW; Moser AE; Singh I; O'Neill BP
    Ann Neurol; 1984 Dec; 16(6):628-41. PubMed ID: 6524872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.